$CUE
Wrapping up the day still thinking about $CUE — at ~$110M market cap you’re getting a validated immunology platform, a Boehringer Ingelheim partnership worth up to $345M in milestones + royalties, a CEO who already built one multi-billion dollar biotech, and a Phase 2 catalyst in H2 2026, all while the balance sheet is actually improving — yes it’s high risk, but the risk/reward at this valuation with this setup is hard to ignore. Watching closely into the back half of the year.
Not financial advice. $CUE #Biotech #Immunology #Stocks
Paid promotion @TheFlowShark
Disclaimer: https://t.co/qD6RaYElcw